MyTheragene® Personalized pharmacotherapy based on human DNA. LEARN MORE Pharmacogenomics MyTheragene® Personalized pharmacotherapy based on human DNA Pharmacogenomics is a rapidly evolving division of clinical pharmacology that deals with the research and study of genetically determined alterations that affect: • metabolism (pharmacokinetics) • the action (pharmacodynamics) of drugs in humans. The proteins and enzymes that regulate each individual's response to drugs often show functional differences due to genetic background. MyTheragene® is an innovative multi-gene test, with high sensitivity and specificity, which is based on pharmacogenomic science and analyzes genes related to the metabolic pathway of drugs. It helps the doctor to choose the most appropriate medicine and the dosage for the best response of each patient. In this way the highest possible efficiency of the treatment is achieved, significantly reducing the cost and the time of treatment and / or management of the disease/syndrome for the patient and the doctor. The test analyzes the metabolic path of each patient for over 500 drugs related to simple and everyday diseases such as headaches, high blood pressure, etc. but also with difficult to manage diseases and disorders such as schizophrenia, depression, neurogenic disorders, etc. For more scientific and technical information you can contact us: scientific.support@genekor.com MyTheragene® analyzes the effect of the drugs on the following fields: Cardiology Cardiology Psychiatry Oncology Endocrinology Gynecology Gastroenterology Immunology Dermatology Nephrology Ophthalmology Urology Otolaryngology Rheumatology Hematology MyTheragene® analysis is suitable for any person receiving or about to receive medication, but it is necessary for the following groups of patients: • Patients with complex medication regimens and several health conditions • Patients who show little or no response to current medication • Patients who experience side effects from current treatment • Patients with chronic diseases • Patients with rare or severe disorders • Patients with allergies to drugs MyTheragene Genes Panel ABCB1 ABCG2 ADRA2A ANK1 APOE COMT CYP1A2 CYP2B6 CYP2C19 CYP2C8 CYP2C9 CYP2D6 CYP3A4 CYP3A5 DBH DPYD DRD1 DRD4 F2 F5 FLOT1 GABRA6 GABRP GRIK4 HCP5 HLA-A HTR2A HTR2C ITGB3 KIF6 MTHFR OPRD1 OPRK1 OPRM1 SLCO1B1 TPMT UGT1A1 UGT2B15 UGT2B7 VKORC1 The future is now Many drugs already include pharmacogenomic information in the enclosed leaflets, highlighting the need to adapt prescriptions according to the individual's genetic profile. The test is performed on blood or saliva and the result time is 10 working days. About Contact us © 2017 GENEKOR MEDICAL S.A. All rights reserved | Terms of Use | Secure Transactions | Sitemap Committed to biotechnological innovation Change cookies consent Revoke cookies consent